ASCO GU 2008 - Androgen Receptor Reactivation After Androgen Deprivation Therapy - Highlight

UroToday.com - Dr. Balk discussed the modest clinical benefit of AR antagonists in addition to androgen-deprivation therapy (ADT). However, AR is expressed at levels that are comparable to primary CaP, although the expression may not be heterogeneous. It is possible that there is cell cycle regulation to AR expression. He pointed out that progression to castration resistant CaP is associated with substantial reactivation of AR transcriptional activity.

More: continued here

Filed under: Endocrinology on February 26th, 2008